How To Write A CER: The Complete Clinical Evaluation Report Guide

A Clinical Evaluation Report (CER) is a systematic, ongoing process of collecting, appraising, and analyzing clinical data regarding a medical device to verify its clinical safety and performance. Authors must adhere to MEDDEV 2.7/1 rev 4 and EU MDR 2017/745 guidelines, ensuring that the benefit-risk ratio remains favorable throughout the lifecycle of the product.

Pre-Evaluation Planning and Regulatory Preparation

Writing a compliant CER requires a rigorous, methodical approach to data synthesis, pulling from pre-clinical testing, post-market surveillance (PMS), and human clinical investigations. The process requires cross-functional coordination between regulatory affairs, clinical operations, and quality assurance personnel to align with current international standards.

• Essential Tools & Inputs: Access to MEDDEV 2.7/1 rev 4, EU MDR 2017/745, ISO 14155, ISO 14971 risk management files, post-market surveillance reports (PMSR), Periodic Safety Update Reports (PSUR), and literature review management software.
• Mandatory Prerequisites: Comprehensive understanding of the device's intended purpose, target patient populations, anatomical use sites, technical specifications, and equivalent device profiles.
• Budget & Timeline Benchmarks: Depending on device classification (Class IIa, IIb, or III) and available clinical data, preparation spans 6 to 16 weeks with allocated resources for database subscriptions (PubMed, Embase) and independent medical writers.

Step-by-Step Clinical Evaluation Report Execution

Step 1: Define the Scope and Compile the Clinical Evaluation Plan (CEP)

Establish the foundational framework by authoring the Clinical Evaluation Plan (CEP), which dictates how the evaluation will proceed. Define the device description, its accessories, the medical indications, contraindications, target user groups, and the clinical claims made by the manufacturer. Outline the methodologies for literature searching and criteria for data appraisal.

Pro-Tip: Ensure the CEP explicitly lists state-of-the-art alternative treatments and diagnostic methods, as notified bodies heavily scrutinize whether the device addresses an unmet clinical need or offers clear advantages over existing standards of care.

Step 2: Conduct Systematic Literature Reviews and Data Retrieval

Execute reproducible, methodical literature searches across biomedical databases such as MEDLINE, Embase, and the Cochrane Library. Formulate search strings using Boolean operators that capture both safety and performance endpoints for the subject device and its direct equivalents. Screen titles, abstracts, and full texts against predefined inclusion and exclusion criteria.

Warning: Never use vague search strings or single-database queries. Notified bodies will reject CERs that fail to demonstrate an exhaustive, unbiased search methodology conforming to PRISMA guidelines.

Step 3: Appraise Clinical Data Quality and Relevance

Evaluate every retrieved data article and internal company dataset for scientific validity, relevance, and reliability. Apply the methodological quality scoring framework outlined in MEDDEV 2.7/1 rev 4, scoring articles based on parameters such as design quality, execution rigor, statistical power, and applicability to the specific device under evaluation.

1. Categorize all accepted data points into safety data, performance data, and adverse event logs.
2. Filter out low-quality studies that suffer from high bias, poor endpoint definition, or lack of statistical significance.
3. Weigh clinical data generated from the exact subject device significantly higher than data sourced from equivalent or similar legacy devices.

Step 4: Analyze Data for Safety, Performance, and Benefit-Risk Profile

Synthesize the appraised data into a cohesive analysis that addresses every claim made in the device labeling and marketing materials. Calculate quantitative safety endpoints such as incidence rates of serious adverse events (SAEs), device deficiencies, and user-related errors. Compare these findings against acceptable thresholds defined in the risk management file.

1. Aggregate all Post-Market Surveillance (PMS) data, including complaint trends, corrective and preventive actions (CAPAs), and global adverse event databases (MAUDE, vigilance reports).
2. Contrast the clinical performance of the device against current state-of-the-art benchmarks identified during the literature review phase.
3. Formulate a definitive benefit-risk determination, proving that clinical benefits outweigh residual risks when the device is used according to instructions.

Technical Parameters and Methodological Comparison

Common CER Failures and Field Fixes

Authors frequently encounter critical deficiencies during notified body audits that delay CE mark certification or market access. Addressing these structural flaws proactively prevents costly submission rejections.

• Root Cause: Inadequate demonstration of equivalence between the subject device and the chosen comparable device.
  
  
  • Actionable Fix: Ensure technical, biological, and clinical characteristics match identically. If minor differences exist, provide rigorous scientific justification explaining why those differences do not impact safety or performance profiles.
• Root Cause: Outdated literature searches that do not reflect the current state of the art.
  
  
  • Actionable Fix: Conduct a fresh, updated literature search within three months of the final submission date to capture newly published clinical studies and post-market safety signals.
• Root Cause: Disconnect between the risk management file (ISO 14971) and the conclusions drawn in the CER.
  
  
  • Actionable Fix: Cross-reference every residual risk listed in the risk assessment matrix with the clinical data appraisal section to confirm that all identified hazards are mitigated and accounted for in human use.
• Root Cause: Over-reliance on generic safety data rather than device-specific clinical investigations or PMS registries.
  
  
  • Actionable Fix: Supplement literature reviews with direct post-market clinical follow-up (PMCF) data, company-sponsored registry results, or targeted customer feedback evaluations.

Frequently Asked Questions

What is the difference between a CEP and a CER?

The Clinical Evaluation Plan (CEP) is the proactive protocol written prior to conducting the evaluation that outlines methodology, search criteria, and endpoints. The Clinical Evaluation Report (CER) is the comprehensive final document that executes the plan, analyzes the retrieved data, and presents the final benefit-risk conclusions.

How often must a Clinical Evaluation Report be updated?

For Class III devices and implantable devices, the CER must be updated annually as part of the Periodic Safety Update Report (PSUR). For Class IIa and IIb devices, updates occur whenever new clinical data with potential impact on safety or benefit-risk arises, or at least every two years as part of routine post-market surveillance.

Can legacy devices use literature alone for a CER?

Legacy devices with a long history of clinical use can rely on sufficient, well-documented literature and post-market surveillance data to establish equivalence and safety. However, notified bodies demand higher scrutiny and rigorous justification if the device lacks prospective clinical trial data under current regulatory frameworks.

Who is qualified to write a Clinical Evaluation Report?

Authors must possess documented medical, scientific, or regulatory expertise relevant to the medical device category. According to MEDDEV 2.7/1 rev 4, authors generally require a university degree in a relevant scientific discipline alongside documented experience in conducting literature reviews, clinical research methodology, and medical writing.

Master Regulatory Compliance Today

Streamline your medical device submission process by mastering advanced clinical evaluation methodologies and ensuring strict alignment with EU MDR standards. Begin structuring your next compliant regulatory document with confidence and precision.